Research Topics
| C M RubinoSummaryAffiliation: Ordway Research Institute Country: USA Publications
|
Detail Information
Publications
Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatricsChristopher M Rubino
Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206 1072, USA
Paediatr Drugs 9:361-9. 2007..Application of these PK-PD principles allows rational dosage regimen selection, both for serious infections in critically ill children and for non-life-threatening community-acquired infections...
Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremiaChristopher M Rubino
Institute for Clinical Pharmacodynamics, Ordway Research Institute, Inc, Albany, New York, USA
Antimicrob Agents Chemother 53:4422-8. 2009..These results suggest that dose modification may be warranted in patients weighing >110 kg. However, the mild nature of the observed relationships for Vc suggest that dosing adjustments are not necessary for elderly patients...- Population pharmacokinetic model for gatifloxacin in pediatric patientsChristopher M Rubino
Cognigen Corporation, Buffalo, NY, USA
Antimicrob Agents Chemother 51:1246-52. 2007..The success of this strategy provides a model for future pediatric drug development programs... 
Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adultsC M Rubino
Institute for Clinical Pharmacodynamics, Ordway Research Institute, 43 British American Boulevard, Latham, NY 12110, USA
Pulm Pharmacol Ther 22:279-85. 2009..Administration of pirfenidone with food has a modest effect on overall exposure but results in lower peak concentrations, which may improve tolerability...- Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical developmentChristopher M Rubino
Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206, USA
Diagn Microbiol Infect Dis 59:67-74. 2007..In conclusion, population pharmacokinetic/pharmacodynamic methods allowed estimation of drug exposure using one sample per patient... - Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infectionsS M Bhavnani
Institute for Clinical Pharmacodynamics, Ordway Research Institute, 43 British American Blvd, Latham, NY 12110, USA
Antimicrob Agents Chemother 54:1207-12. 2010..594. These findings demonstrated the impact of individual and multiple factors on clinical response in the context of drug exposure... - Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymorePaul G Ambrose
Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
Clin Infect Dis 44:79-86. 2007..Over the past 15 years, considerable PK-PD data have been derived from infected patients for many classes of antimicrobial agents. These data provide the opportunity to confirm knowledge gained from animal PK-PD infection models... - Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumoniaSujata M Bhavnani
Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206 1072, USA
Diagn Microbiol Infect Dis 62:99-101. 2008..Such data may be useful to establish prior expectations for the no-treatment effect when conducting noninferiority clinical trials... - Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulationChristopher M Rubino
Institute for Clinical Pharmacodynamics, Ordway Research Institute, 150 New Scotland Avenue, Albany, NY 12208, USA
Antimicrob Agents Chemother 51:4085-9. 2007..15 (0.561 and 5.23), respectively. Simulation results predict that tissue penetration varies considerably and likely explain unexpected clinical outcomes for those patients infected with strains at margins of the MIC distribution... - Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis modelStanley C Gill
Department of Pharmacology, Replidyne, Inc, Louisville, Colorado, USA
Antimicrob Agents Chemother 54:1678-83. 2010..6, 13.4, and 16.4%, respectively, and E(max) was 89.3%. Overall, faropenem demonstrated a high level of activity against B. anthracis in the murine postexposure prophylaxis inhalation model... - Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditisSujata M Bhavnani
Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, New York, USA
Clin Infect Dis 50:1568-74. 2010.... - Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study TeamRonald N Jones
The JONES Group/JMI Laboratories, North Liberty, Iowa, USA
Antimicrob Agents Chemother 47:292-6. 2003..pneumoniae and that gatifloxacin has an overall 14.3% higher probability of achieving clinically important PK-PD target ratios than levofloxacin...